RL
RLYB.US Rallybio Corp
- Market cap
- USD 85.6M
- P/E
- 3.3x
- P/B
- 0.94x
- ROE
- 47.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RLYB.US undervalued?
Graham numberRLYB.US trades 62.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rallybio Corp fundamental analysis
No fundamental analysis for Rallybio Corp yet.
Rallybio Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and…
Full company profileRallybio Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rallybio Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 636K | 858K | 283K |
| Gross Profit | -26.3K | -62.0K | -109K | -167K | -150K | -38.9M | 766K | - |
| Operating Income | -17.6M | -25.3M | -45.6M | -67.9M | -78.9M | -60.5M | -28.1M | -18.4M |
| EBITDA | -17.4M | -25.2M | -45.4M | -67.7M | -78.8M | -60.4M | -28.0M | 50.2M |
| Net Income | -17.6M | -26.4M | -47.0M | -66.7M | -74.6M | -57.8M | -8.98M | 43.5M |
| EPS | -6.34 | -9.51 | -12 | -17 | -15 | -11 | -1.59 | 7.62 |
| Balance Sheet | ||||||||
| Total Assets | 21.6M | 142M | 182M | 180M | 116M | 68.1M | 62.3M | 95.6M |
| Total Liabilities | 4.75M | 5.86M | 6.58M | 11.1M | 9.44M | 6.45M | 4.31M | 3.28M |
| Shareholders' Equity | 16.9M | 136M | 176M | 169M | 106M | 61.7M | 58.0M | 92.3M |
| Cash & Short-term Investments | 19.5M | 140M | 175M | 169M | 110M | 65.5M | 54.7M | 90.7M |
| Total Debt | - | - | - | 555K | 392K | 154K | 176K | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -15.0M | -22.0M | -45.5M | -57.3M | -60.3M | -49.3M | -29.8M | 47.1M |
| Capital Expenditure | 188K | 137K | 333K | 54.0K | 12.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -15.2M | -22.2M | -45.9M | -57.3M | -60.3M | -49.3M | -29.8M | 47.1M |
| Ratios | ||||||||
| ROE | -104.5% | -19.4% | -26.8% | -39.4% | -70.2% | -93.7% | -15.5% | 47.2% |
| ROA | -81.6% | -18.6% | -25.8% | -36.9% | -64.5% | -84.8% | -14.4% | 45.6% |
| Net Profit Margin | - | - | - | - | - | -9,084.1% | -1,046.4% | 15,406.6% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rallybio Corp dividends
Rallybio Corp has not paid dividends in the last 7 fiscal years.
Last stock split: 1:8 on Feb 6, 2026.
Who owns Rallybio Corp
- Insiders 27.10%
- Institutions 72.90%
- Public & others 0.00%
- Shares outstanding 5.60M
- Free float 1.64M
Top funds holding RLYB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 207K | 1.93% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 135K | 1.25% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 56.8K | 0.53% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 53.6K | 0.50% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 15.5K | 0.14% | +20.70% | Sep 2026 |
| Dimensional US Small Cap ETF | 6.68K | 0.06% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 5.89K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 4.51K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 4.41K | 0.04% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 3.14K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.79K | 0.03% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 2.29K | 0.02% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 1.56K | 0.01% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.44K | 0.01% | 0.00% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 1.09K | 0.01% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 795.00 | 0.01% | 0.00% | Sep 2026 |
| Dimensional International Core Eq Acc | 724.00 | 0.01% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 719.00 | 0.01% | 0.00% | Sep 2026 |
| JNL/DFA US Core Equity A | 684.00 | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 684.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding RLYB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ADAR1 Capital Management LLC | 926K | 8.60% | +4,411.09% | Jun 2026 |
| FMR Inc | 795K | 7.38% | +0.16% | Jun 2026 |
| Viking Global Investors LP | 524K | 4.87% | 0.00% | Jun 2026 |
| TPG GP A, LLC | 379K | 3.52% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 377K | 3.50% | +25.35% | Jun 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 301K | 2.79% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 172K | 1.60% | +53.96% | Jun 2026 |
| Renaissance Technologies Corp | 146K | 1.36% | -26.95% | Sep 2026 |
| Almitas Capital LLC | 121K | 1.12% | -36.88% | Jun 2026 |
| Citadel Advisors Llc | 72.2K | 0.67% | +263.07% | Jun 2026 |
| Mariner Wealth Advisors LLC | 50.6K | 0.47% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 47.4K | 0.44% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 32.0K | 0.30% | -9.54% | Jun 2026 |
| BlackRock Inc | 30.3K | 0.28% | +73.46% | Jun 2026 |
| HRT FINANCIAL LLC | 25.7K | 0.24% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 21.5K | 0.20% | +91.49% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 19.5K | 0.18% | +72.50% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 16.8K | 0.16% | +24.16% | Jun 2026 |
| Two Sigma Investments LLC | 16.6K | 0.15% | 0.00% | Jun 2026 |
| State Street Corp | 13.0K | 0.12% | 0.00% | Jun 2026 |
Rallybio Corp company profile
- Company name
- Rallybio Corp
- Ticker
- RLYB.US
- Exchange
- USA Stocks
- Listed since
- Jul 29, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 234 Church Street, New Haven, CT, United States, 06510
- Phone
- 203 859 3820
- Website
- rallybio.com
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Rallybio Corp management
2- Dr. Martin W. MacKay Ph.D.Co-Founder & Chairman · born 1956
- Dr. Stephen Uden M.D., MBBSCo-Founder, President, CEO & Director · born 1958